IMM-001

IMM-001 is an early-stage drug candidate being developed by RapaFusyn Pharmaceuticals for the treatment of unspecified immunological and inflammatory disorders. It is part of the company's proprietary RapaGlues™ platform, which focuses on the development of rapamycin-based macrocyclic molecular glues. These molecules are designed to induce or stabilize interactions between a target protein and an effector protein, such as an E3 ligase for targeted protein degradation or other proteins for non-degradative functional modulation. As of current pipeline reports, IMM-001 is in the hit identification phase of development, and its specific molecular target has not been publicly disclosed.